Background: Constitutive expression and localization of antimicrobial human b-defensin-1 (HBD-1) in human kidneys as a potential mechanism of antimicrobial defense has been previously reported. Inducible expression of human b-defensin-2 (HBD-2) has been described in various epithelial organs but not for the urogenital tract.

No abstract

BACKGROUND The American Joint Committee on Cancer and the Union Internationale Contre le Cancer have acknowledged routine laboratory parameters, such as serum calcium, alkaline phosphatase, hemoglobin, and the erythrocyte sedimentation rate (ESR), as predictors of survival in patients with renal cell carcinoma. The predictive value of these parameters compared with proliferation markers, such as Ki‐67, proliferating cell nuclear antigen (PCNA), topoisomerase II‐α, and p100, has not been determined. METHODS Forty‐eight consecutive patients who underwent nephrectomy for nonmetastatic renal cell carcinoma between 1990 and 1994 were observed up to 120 months postoperatively. Ten of 48 patients developed tumor progression 6–69 months after surgery. Routine preoperative laboratory parameters as well as tumor‐specific data were assessed. Findings were compared with tumor proliferation indices, which were obtained by immunohistochemical staining for nuclear antigens Ki‐67, PCNA, topoisomerase II‐α, and p100 in paraffin embedded tumor tissue. RESULTS Univariate and multivariate statistical analyses demonstrated superiority of routine laboratory values compared with tumor proliferation indices in predicting progression‐free survival and disease‐specific death. The best predictor after tumor size and symptomatic presentation was ESR (P < 0.0001), with ESR values > 70 mm at 2 hours indicating a significantly poorer prognosis. Only the proliferation marker Ki‐67 reached univariate significance at a threshold of 7%. CONCLUSIONS Routine laboratory parameters, such as alkaline phosphatase, lactate dehydrogenase, thrombocyte count, and especially ESR, provided superior long‐term prognostic information for patients with nonmetastatic renal cell carcinoma compared with the molecular tumor proliferation markers Ki‐67, PCNA, topoisomerase II‐α, and p100. Cancer 2004. © 2004 American Cancer Society.

No abstract

No abstract